Comparative Pharmacology
Head-to-head clinical analysis: CORTALONE versus EPIFOAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTALONE versus EPIFOAM.
CORTALONE vs EPIFOAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response, and regulate metabolism.
Epinephrine is a sympathomimetic amine that acts as a non-selective agonist at alpha- and beta-adrenergic receptors. It causes vasoconstriction, bronchodilation, and increased heart rate and contractility.
10-40 mg orally once daily in the morning; for acute exacerbations, up to 60 mg/day divided into 2-4 doses.
Not applicable; EPIFOAM is a topical foam containing pramoxine hydrochloride 1% and aluminum acetate, used for hemorrhoidal symptoms. No systemic dosing.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
2-3 hours (terminal elimination half-life); clinically, this supports every 4-6 hour dosing intervals for consistent effect.
Primarily renal (60-70% as unchanged drug), with 10-20% biliary/fecal.
Primarily hepatic metabolism to inactive glucuronide conjugates; renal excretion of metabolites accounts for ~80% of elimination, with ~15% biliary/fecal. Less than 5% excreted unchanged in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid